No increased risk of cardiovascular events with dapagliflozin in elderly patients with type 2 diabetes mellitus, cardiovascular disease and hypertension

被引：0
|
作者：
Gause-Nilsson, I. [1 ]
Sonesson, C. [1 ]
Johansson, P. A. [1 ]
Johnsson, E. [1 ]
机构：
[1] AstraZeneca, Molndal, Sweden
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
754
引用
收藏
页码：S362 / S363
页数：2
相关论文
共 50 条
  • [1] No Increased Risk of Cardiovascular Events with Dapagliflozin in Elderly Patients with Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Johansson, Peter A.
    Sugg, Jennifer E.
    Johnsson, Eva
    [J]. DIABETES, 2015, 64 : A4 - A4
  • [2] Dapagliflozin Treatment for Type 2 Diabetes Mellitus Patients With Comorbid Cardiovascular Disease and Hypertension
    Cefalu, William T.
    Leiter, Lawrence A.
    Debruin, Tjerk W.
    Gausenilsson, Ingrid
    Sugg, Jennifer
    Parikh, Shamik J.
    [J]. DIABETES, 2012, 61 : A271 - A271
  • [3] Efficacy and safety of dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension
    Cefalu, W.
    Leiter, L.
    De Bruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    [J]. DIABETOLOGIA, 2012, 55 : S305 - S305
  • [4] Dapagliflozin treatment for type 2 diabetes mellitus patients with a history of cardiovascular disease
    Leiter, L.
    Cefalu, W.
    DeBruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    [J]. DIABETOLOGIA, 2012, 55 : S310 - S311
  • [5] Risk factors of cardiovascular disease in Romanian elderly patients with type 2 diabetes mellitus
    Gherbon, A. M. C.
    Gherbon, A.
    Frandes, M.
    Bercea, V.
    Timar, B.
    Timar, R.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [6] Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients With a History of Cardiovascular Disease
    Leiter, Lawrence A.
    Cefalu, William T.
    Debruin, Tjerk W.
    Gausenilsson, Ingrid
    Sugg, Jennifer
    Parikh, Shamik J.
    [J]. DIABETES, 2012, 61 : A287 - A287
  • [7] Cardiovascular disease risk in patients with type 2 diabetes and hypertension
    Kawada, Tomoyuki
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 (02)
  • [8] Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Song, Do Kyeong
    Hong, Young Sun
    Sung, Yeon-Ah
    Lee, Hyejin
    [J]. PLOS ONE, 2024, 19 (02):
  • [9] Endocan is Related to Increased Cardiovascular Risk in Type 2 Diabetes Mellitus Patients
    Klisic, Aleksandra
    Kotur-Stevuljevic, Jelena
    Ninic, Ana
    [J]. METABOLIC SYNDROME AND RELATED DISORDERS, 2023, 21 (07) : 362 - 369
  • [10] Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk
    Sonesson, C.
    Frederich, R.
    Johansson, P. A.
    Gause-Nilsson, I.
    Langkilde, A. M.
    List, J. F.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1072 - 1072
12345